developed a brain shuttle construct for treatment of Alzheimer’s disease through fusing the Fab fragment of an anti-TfR monoclonal antibody to the Fc region at the C-terminal end of the heavy chain of an anti-Aβ mAb (mAb31) (Niewoehner et al., 2014). The gene discussed is TFRC; the disease is early-onset autosomal dominant Alzheimer disease.